JAHH is a Phase 2, multicenter, randomized, double-blind, placebo controlled, outpatient, 24-week study evaluating the efficacy and safety of baricitinib 4-mg and 2-mg in patients with SLE receiving standard therapy. Approximately 300 patients will be randomized 1:1:1 to receive baricitinib 4-mg daily, baricitinib 2-mg daily, or placebo (100 patients per treatment group).